PCN122 Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.259
https://www.valueinhealthjournal.com/article/S1098-3015(20)32515-8/fulltext
Section Title :
Section Order :
10203
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32515-8&doi=10.1016/j.jval.2020.08.259